The “right-to-try” bill heads to President Trump’s desk for signing after passing the House of Representatives; the FDA said certain gene therapies in development can qualify for quicker review, starting with hemophilia; brand-name drug makers have raised prices by double-digit percentages since 2012, with 47 drugs costing Medicare and Medicaid nearly $12 billion in 2016.
The “right-to-try” bill heads to President Trump’s desk for signing after passing the House of Representatives for the second time by 250-169. The bill, which would allow terminally ill patients to bypass the FDA and request experimental drugs that have cleared phase 1 safety trials directly from drug companies, passed largely along party lines. The Senate passed the bill in August 2017, and the House approved its own version in March. That version was opposed less by medical groups, but then the legislation stalled. House leaders decided to pass the Senate version instead, The Washington Post reported.The FDA said certain gene therapies in development can qualify for quicker review, STAT reported. Commissioner Scott Gottlieb, MD, said that hemophilia is the first disease the FDA will target with its new policy. Under the new policy, gene therapies for hemophilia could be evaluated based on whether the therapy increases clotting proteins in the blood, regardless of whether the therapy actually causes the patient to bleed less.
Brand-name drug makers blamed by the Trump administration for potentially stalling generic competition have raised prices by double-digit percentages since 2012, with 47 drugs costing Medicare and Medicaid nearly $12 billion in 2016, Kaiser Health News reported. Kaiser’s analysis said the spending totals don’t include rebates, which pharmaceutical companies return to the government. The rebates ranged from 9.5% to 26.3% for Medicare Part D in 2014.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More